Related Experiment Video
Updated: Apr 11, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Hong Kong consensus recommendations on the management of hepatocellular carcinoma
Ronnie Tung-Ping Poon1, Tom Tan-To Cheung1, Philip Chong-Hei Kwok2
1Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR (China).
Insights
Hepatocellular carcinoma (HCC) is common in Hong Kong due to chronic hepatitis B (CHB). This guideline provides local recommendations for HCC management and antiviral therapy to reduce incidence and recurrence in CHB patients.
Area of Science:
- Hepatology
- Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong, linked to a high incidence of chronic hepatitis B (CHB) infection.
- HCC ranks as the fourth most common cancer in men and seventh in women, representing a significant cause of cancer mortality in Hong Kong.
- While diverse HCC treatment options are accessible locally, a unified consensus on their application is lacking.
Purpose of the Study:
- To establish local recommendations for the management of Hepatocellular Carcinoma (HCC).
- To provide guidance on the effective deployment of various HCC treatment modalities for patients across different disease stages.
- To incorporate antiviral therapy recommendations for reducing HCC incidence and recurrence in chronic hepatitis B (CHB) patients.
Main Methods:
- A multidisciplinary group of Hong Kong clinicians convened for a series of meetings from May to October 2013.
- The group comprised liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists.
- Recommendations were formulated based on current evidence and expert clinical opinion in HCC management.
Main Results:
- Development of comprehensive local recommendations for HCC management.
- Detailed guidance on utilizing available HCC treatment modalities tailored to patient disease stages.
- Inclusion of specific recommendations for antiviral therapy in CHB patients to mitigate HCC risk and recurrence.
Conclusions:
- The formulated recommendations offer a structured approach to HCC management in Hong Kong.
- These guidelines integrate the latest evidence and clinical insights for optimal patient care.
- A key feature is the guidance on antiviral therapy, addressing HCC prevention and post-treatment recurrence in the context of CHB.
Background:
Hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection; HCC is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong. The full spectrum of treatment modalities for HCC is available locally; however, there is currently no local consensus document detailing how these modalities should be used.
Summary:
In a series of meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians - liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists - convened to formulate local recommendations on HCC management. These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, and give detailed guidance on how to deploy these modalities effectively for patients in various disease stages.
Key Messages:
Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
